Susquehanna International Group’s TScan Therapeutics TCRX Stock Holding History

Susquehanna International Group’s Portfolio TCRX Stock Details TCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$159K	Sell	157,228 -58,905	-27%	-$62.9K	﹤0.01%	11940
2025 Q4	$216K	Buy	216,133 +136,373	+171%	+$197K	﹤0.01%	10714
2025 Q3	$145K	Sell	79,760 -64,612	-45%	-$114K	﹤0.01%	11306
2025 Q2	$209K	Buy	144,372 +95,769	+197%	+$138K	﹤0.01%	11118
2025 Q1	$67.1K	Buy	48,603 +22,768	+88%	+$49.2K	﹤0.01%	11758
2024 Q4	$78.5K	Buy	25,835 +15,659	+154%	+$71K	﹤0.01%	11476
2024 Q3	$50.7K	Buy	+10,176	New	+$61.4K	﹤0.01%	11371
2024 Q2	–	Sell	-297,902	Closed	-$2.37M	–	13219
2024 Q1	$2.37M	Buy	297,902 +193,954	+187%	+$1.22M	﹤0.01%	4969
2023 Q4	$606K	Buy	103,948 +87,033	+515%	+$398K	﹤0.01%	8189
2023 Q3	$43.3K	Buy	+16,915	New	+$39.5K	﹤0.01%	11360

Other funds holding TCRX

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DMC

Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Susquehanna International Group's TCRX Position: Q1 2026 in Review

Susquehanna International Group reduced its TScan Therapeutics (TCRX) stake by 27% in Q1 2026, selling an estimated $62.9K and leaving 157,228 shares worth $159K. The position accounts for ﹤0.01% of the portfolio, ranked #11940.

Susquehanna International Group first reported a position in TCRX in Q3 2023 and has held it in 10 quarters since. The position peaked at $2.37M in Q1 2024. 60 funds tracked by Wall St. Rank hold TCRX as of Q1 2026.

Susquehanna International Group held 157,228 shares of TScan Therapeutics worth $159K as of Q1 2026.
Susquehanna International Group sold 58,905 TScan Therapeutics shares in Q1 2026, an estimated $62.9K.
TScan Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #11940 holding.
Susquehanna International Group first reported a position in TScan Therapeutics in Q3 2023 and has held it in 10 quarters since.
Susquehanna International Group's TScan Therapeutics position peaked at $2.37M in Q1 2024.
60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.